【产品介绍】：

生物活性：Abiraterone acetate-d4 is the deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Abiraterone acetate-d4 相关抗体:
Cytochrome C Antibody
Cytochrome P450 17A1 Antibody
Aromatase Antibody
CYP11A1 Antibody
Cytochrome P450 1B1 Antibody (YA1836)
Adrenodoxin Antibody (YA2005)
Cytochrome P450 27A1 Antibody (YA2163)
Cytochrome P450 2C9 Antibody (YA2166)
Cytochrome P450 2E1 Antibody (YA2302)
Cytochrome P450 Reductase Antibody (YA2619)
Thromboxane A Synthase Antibody (YA2670)
Cytochrome P450 3A4 Antibody (YA3365)
HSD11B1 Antibody (YA3376)
Cytochrome P450 17A1 Antibody (YA786)
CYP2E1 Antibody
CYP1A2 Antibody
PLSCR3 Antibody (YA1672)
PROX1 Antibody (YA1754)
Cytochrome P450 4A Antibody (YA2087)
Cytochrome P450 24A1 Antibody (YA2121)
Cytochrome P450 26A1 Antibody (YA2259)
COX5B Antibody (YA2550)
Steroidogenic Factor 1 Antibody (YA3166)
Dynein Light Chain Tctex Type 1 Antibody (YA3263)
Cytochrome P450 2D6 Antibody (YA3384)
分子量：395.57
Formula：C26H29D4NO2
非标记 CAS：154229-18-2
中文名称：乙酸阿比特龙酯 d4
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (532 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387-400.
 [Content Brief]
[3]. Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1;72(9):2176-82.
 [Content Brief]
[4]. Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1;18(13):3571-9.
 [Content Brief]
[5]. Lee GT, et al. Intracrine androgen biosynthesis in renal cell carcinoma. Br J Cancer. 2017 Mar 28;116(7):937-943.
 [Content Brief]
[6]. A O'Donnell, et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancervolume 90, pages2317–2325 (2004)